chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 43.0
Sex: F
Vaccine: FLU3
Symptoms: Full blood count normal, Haemorrhage, Hypersensitivity, Laboratory test normal, Pruritus
Clinical narrative: This case was reported by a physician and described the occurrence of hives in a 43-year-old female subject who was vaccinated with Fluarix (GlaxoSmithKline). In early November 2007 the subject received unspecified dose of Fluarix at 0.5 ml. At an unspecified time after vaccination with Fluarix, the subject experienced hives with itching to the point of producing blood. This has occurred three times since receiving Fluarix. In addition, the subject underwent a spirometry test for respirator use and she did not pass. At the time of reporting the events of hives, itching and the abnormal spirometry test were unresolved. The outcome of bleeding skin was not specified. Follow-up received on 25 January 2008 via the physician. Relevant history included an allergy to walnuts. She reported that on 10 November 2007 the subject experienced hives, itching, abnormal spirometry and skin bleeding. The subject was diagnosed with an allergic reaction of unknown etiology. On 05 December 2007, results of a CBC, chemistry screen and sedimentation rate were all normal. On 13 December 2007, all the hives, itching, abnormal spirometry, skin bleeding and the allergic reaction of unknown etiology had improved. The physician considered that the events were not serious and possibly related to the use of Fluarix. A separate summary for the events was provided by the physician which included the following information. 04 December 2007. It was noted that the influenza injection was received and a week or so after that itching which got to the point that the subject would scratch herself to the point of bleeding. Symptoms were noted to include perfuse itching especially at night, no shortness of breath or feeling of throat closing. Subject did not increased nasal congestion and post nasal drip. On 04 December 2007, the subject was without symptoms. Blood work was ordered and subject advised to see physician and an allergies. 05 December 2007: Blood work was performed. CBC with differential, chemistry screen and sedimentation rate were all normal. 06 December 2007: subject seen by another physician. Subject was noted to have had a "wheal and flare" reaction of upper arm and back without shortness of breath, hypotension or other signs and symptoms of anaphylaxis. Diagnosed with an allergic reaction of unknown etiology. Treated with 40 mg Kenalog intramuscular, Synalar cream 0.025 percent to pruritic areas and Medrol dose pack. Referred to allergist. 22 January 2008: Physician contacted the subject via phone. Subject noted that she feels well. Noted that she does experienced rare episodes of pruritus which she usually can bring on herself by just scratching her skin. Occurs in small areas is of short duration responding almost immediately to the Synalar cream Denies any other symptoms and did not see an allergist.
Age: 43.0
Sex: F
Vaccine: FLU3
Symptoms: Red blood cell sedimentation rate normal, Scratch, Spirometry abnormal, Urticaria
Clinical narrative: This case was reported by a physician and described the occurrence of hives in a 43-year-old female subject who was vaccinated with Fluarix (GlaxoSmithKline). In early November 2007 the subject received unspecified dose of Fluarix at 0.5 ml. At an unspecified time after vaccination with Fluarix, the subject experienced hives with itching to the point of producing blood. This has occurred three times since receiving Fluarix. In addition, the subject underwent a spirometry test for respirator use and she did not pass. At the time of reporting the events of hives, itching and the abnormal spirometry test were unresolved. The outcome of bleeding skin was not specified. Follow-up received on 25 January 2008 via the physician. Relevant history included an allergy to walnuts. She reported that on 10 November 2007 the subject experienced hives, itching, abnormal spirometry and skin bleeding. The subject was diagnosed with an allergic reaction of unknown etiology. On 05 December 2007, results of a CBC, chemistry screen and sedimentation rate were all normal. On 13 December 2007, all the hives, itching, abnormal spirometry, skin bleeding and the allergic reaction of unknown etiology had improved. The physician considered that the events were not serious and possibly related to the use of Fluarix. A separate summary for the events was provided by the physician which included the following information. 04 December 2007. It was noted that the influenza injection was received and a week or so after that itching which got to the point that the subject would scratch herself to the point of bleeding. Symptoms were noted to include perfuse itching especially at night, no shortness of breath or feeling of throat closing. Subject did not increased nasal congestion and post nasal drip. On 04 December 2007, the subject was without symptoms. Blood work was ordered and subject advised to see physician and an allergies. 05 December 2007: Blood work was performed. CBC with differential, chemistry screen and sedimentation rate were all normal. 06 December 2007: subject seen by another physician. Subject was noted to have had a "wheal and flare" reaction of upper arm and back without shortness of breath, hypotension or other signs and symptoms of anaphylaxis. Diagnosed with an allergic reaction of unknown etiology. Treated with 40 mg Kenalog intramuscular, Synalar cream 0.025 percent to pruritic areas and Medrol dose pack. Referred to allergist. 22 January 2008: Physician contacted the subject via phone. Subject noted that she feels well. Noted that she does experienced rare episodes of pruritus which she usually can bring on herself by just scratching her skin. Occurs in small areas is of short duration responding almost immediately to the Synalar cream Denies any other symptoms and did not see an allergist.
Age: 74.0
Sex: M
Vaccine: FLU3
Symptoms: Pain
Clinical narrative: This case was reported by a pharmacist and described the occurrence of pain all over body in a 74-year-old male subject who was vaccinated with Fluarix (GlaxoSmithKline).  No adverse events following previous vaccinations.  On 20 November 2007 at 09:45 the subject received 1st dose of Fluarix (.5 ml, left arm).  In December 2007, approximately 2 weeks after vaccination with Fluarix, the subject experienced pain all over body.  The subject has not required any treatment, but plans to see his physician regarding the all over body pain.  At the time of reporting the event was unresolved.  The pharmacist considered the event was possibly related to vaccination with Fluarix.
Sex: U
Vaccine: FLU3
Symptoms: Drug ineffective, Influenza, Laboratory test abnormal
Clinical narrative: This case was reported by a pharmacist and described the occurrence of influenza in an adult subject of unspecified gender who was vaccinated with Fluarix (GlaxoSmithKline).  On an unspecified date in 2007, the subject received unspecified dose of Fluarix (unknown).  At an unspecified time after vaccination with Fluarix, the subject experienced influenza and lack of efficacy.  The pharmacist did not have all the details regarding the event, but did confirm at least two weeks or more had passed since the administration of Fluarix.  Relevant test results included a "quick flu test" that diagnosed the subject with the flu.  At the time of reporting the outcome of the events were unspecified.
Sex: U
Vaccine: FLU3
Symptoms: Influenza, Influenza serology positive, Vaccination failure
Clinical narrative: This case was reported by a pharmacist and described the occurrence of influenza in an adult subject of unspecified gender who was vaccinated with FLUARIX (GlaxoSmithKline). On an unspecified date in 2007, the subject received unspecified dose of Fluarix (unknown). At an unspecified time after vaccination with Fluarix, the subject experienced influenza and lack of efficacy. The pharmacist did not have all the details regarding the event, but did confirm at least two weeks or more had passed since the administration of Fluarix. Relevant test results included a "quick flu test" that diagnosed the subject with the flu. At the time of reporting the outcome of the events were unspecified.
Sex: F
Vaccine: FLU3
Symptoms: Pain, Paraesthesia
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of arm tingling in a female subject of unspecified age who was vaccinated with Influenza vaccine (manufacturer unspecified). On an unspecified date the subject received unspecified dose if Influenza vaccine (unknown). At an unspecified time after vaccination with Influenza vaccine, the subject experienced arm tingling that went away 4-5 hours after the vaccine was administered and minor soreness for a couple of days. At the time of reporting the outcome of the events were unspecified.
Age: 31.0
Sex: F
Vaccine: FLU3
Symptoms: Rash generalised
Clinical narrative: This case was reported by a physician and described the occurrence of generalized rash in a 31-year-old female subject who was vaccinated with Fluarix (GlaxoSmithKline).  On 28 November 2007 the subject received unspecified dose of Fluarix (.5 ml, unknown, right arm).  On 02 December 2007, 4 days after vaccination with Fluarix, the subject experienced generalized rash on multiple body parts.  The subject was treated with steroid injection and topical, as well as Claritin.  At the time of reporting the event was improved.  Follow-up information was received on 11 February 2008 via a physician, who reported that no biopsy was performed on the rash.  At the time of reporting, the event was resolved.  The reporting physician considered the event to be related to vaccination with Fluarix.
Sex: U
Vaccine: DTAP, FLU3, HEP, HEPA
Symptoms: Accidental overdose, Dysgeusia, Incorrect route of drug administration
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with FLUARIX, GlaxoSmithKline.  Previous and/or concurrent vaccination included DTaP; manufacturer unspecified given on 9 December 2007; hepatitis B vaccine recombinant; manufacturer unspecified given on 9 December 2007; hepatitis A vaccine inactivated; manufacturer unspecified given on 9 December 2007.  On 9 December 2007 the subject received unspecified dose of FLUARIX (.5 ml, unknown) intranasally (intramuscular formulation administered by other route) and experienced a funny taste.  The same day, the subject was later vaccinated with FLUARIX and experienced accidental overdose.  No other adverse events were reported.  In December 2007, the events were resolved.  Outcome of accidental overdose was not specified.  The healthcare professional considered the events were probably related to vaccination with FLUARIX (causality not provided for accidental overdose).  Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "Flumist" and administered intranasally.  There were no other adverse events other than "bad taste."
Sex: U
Vaccine: DTAP, FLU3, HEP, HEPA
Symptoms: Accidental overdose, Dysgeusia, Wrong drug administered
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with Fluarix (GlaxoSmithKline). Previous and/or concurrent vaccination included DTaP; manufacturer unspecified given on 9 December 2007; hepatitis B vaccine recombinant; manufacturer unspecified given on 9 December 2007; hepatitis A vaccine inactivated; manufacturer unspecified given on 9 December 2007. On 09 December 2007 the subject received unspecified dose of Fluarix (.5 ml, unknown) intranasally (intramuscular formulation administered by other route) and experienced a funny taste. The same day, the subject was later vaccinated with Fluarix and experienced accidental overdose. No other adverse events were reported. In December 2007, the events were resolved. Outcome of accidental overdose was not specified. The healthcare professional considered the events were probably related to vaccination with Fluarix (causality not provided for accidental overdose). Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "Flumist" and administered intranasally. There were no other adverse events other than "bad taste."
Sex: U
Vaccine: DTAP, FLU3, HEP, HEPA
Symptoms: Accidental overdose, Dysgeusia, Incorrect route of drug administration
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with FLUARIX (GlaxoSmithKline). Previous and/or concurrent vaccination included diphtheria and tetanus toxoids and acellular pertussis vaccine; manufacturer unspecified given on 9 December 2007, hepatitis B vaccine recombinant ; manufacturer unspecified given on 9 December 2007; hepatitis A vaccine inactivated; manufacturer unspecified given on 9 December 2007. On 9 December 2007 the subject received unspecified dose of FLUARIX (.5 ml, unknown) intranasally (intramuscular formulation administered by other route) and experienced a funny taste. The same day, the subject was later vaccinated with FLUARIX and experienced accidental overdose. No other adverse events were reported. In December 2007, the events were resolved. Outcome of accidental overdose was not specified. The healthcare professional considered the events were probably related to vaccination with FLUARIX (causality not provided for accidental overdose). Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "FLUMIST" and administered intranasally. There were no other adverse events other than "bad taste."
Sex: U
Vaccine: DTAP, FLU3, HEP, HEPA
Symptoms: Accidental overdose, Dysgeusia, Incorrect route of drug administration
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with FLUARIX (GlaxoSmithKline). Previous and/or concurrent vaccination included diphtheria and tetanus toxoids and acellular pertussis vaccine ; manufacturer unspecified given on 9 December 2007; hepatitis B vaccine recombinant ; manufacturer unspecified given on 9 December 2007; hepatitis A vaccine inactivated ;manufacturer unspecified given on 9 December 2007. On 9 December 2007 the subject received unspecified dose Fluarix (.5 ml, unknown) intranasally (intramuscular administered by other route) and experienced a funny taste. The same day, the subject was later vaccinated with Fluarix and experienced accidental overdose. No other adverse events were reported. In December 2007, the events were resolved. Outcome of accidental overdose was not specified. The healthcare professional considered the events were probably related to vaccination with Fluarix (causality not provided for accidental over dose). Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "Flumist" and administered intranasally. There were no other adverse events other than "bad taste."
Sex: U
Vaccine: FLU3, HEP, HEPA, TD
Symptoms: Accidental overdose, Dysgeusia, Incorrect route of drug administration
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with Fluarix (GlaxoSmithKline).  Previous and/or concurrent vaccination included DTaP; manufacturer unspecified given on 9 December 2007; Hep B; manufacturer unspecified given on 9 December 2007; Hep A; manufacturer unspecified given on 9 December 2007.  On 9 December 2007 the subject received unspecified dose of Fluarix (.5 ml, unknown) intranasally (intramuscular formulation administered by other route) and experienced a funny taste.  The same day, the subject was later vaccinated with Fluarix and experienced accidental overdose.  No other adverse events were reported.  In December 2007, the events were resolved.  Outcome of accidental overdose was not specified.  The healthcare professional considered the events were probably related to vaccination with Fluarix (causality not provided for accidental overdose).  Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "Flumist" and administered intranasally.  There were no other adverse events other than "bad taste."
Sex: U
Vaccine: DTAP, FLU3, HEP, HEPA
Symptoms: Accidental overdose, Dysgeusia, Incorrect route of drug administration
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with Fluarix (GlaxoSmithKline). Previous and/or concurrent vaccination included DTaP; manufacturer unspecified given on 9 December 2007; hepatitis B vaccine recombinant; manufacturer unspecified given on 9 December 2007. On 9 December 2007 the subject received unspecified dose of Fluarix (.5 ml, unknown) intranasally (intramuscular formulation administered by other route) and experienced a funny taste. The same day, the subject was later vaccinated with Fluarix and experienced accidental overdose. No other adverse events were reported. In December 2007, the events were resolved. Outcome of accidental overdose was not specified. The healthcare professional considered the events were probably related to vaccination with Fluarix (causality not provided for accidental overdose). Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "Flumist" and administered intranasally. There were no other adverse events other than "bad taste."
Sex: U
Vaccine: DTAP, FLU3, HEP, HEPA
Symptoms: Accidental overdose, Dysgeusia, Incorrect route of drug administration
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with FLUARIX (GlaxoSmithKline). Previous and/or concurrent vaccination included diphtheria and tetanus toxoids and acellular pertussis vaccine ;manufacturer unspecified given on 9 December 2007; hepatitis B vaccine recombinant ;manufacturer unspecified given on 9 December 2007; hepatitis A vaccine inactivated ;manufacturer unspecified given on 9 December 2007. On 9 December 2007 the subject received unspecified dose Fluarix (.5 ml, unknown) intranasally (intramuscular administered by other route) and experienced a funny taste. The same day, the subject was later vaccinated with Fluarix and experienced accidental overdose. No other adverse events were reported. In December 2007, the events were resolved. Outcome of accidental overdose was not specified. The healthcare professional considered the events were probably related to vaccination with Fluarix (causality not provided for accidental over dose). Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "Flumist" and administered intranasally. There were no other adverse events other than "bad taste."
Sex: U
Vaccine: DTAP, FLU3, HEP, HEPA
Symptoms: Accidental overdose, Dysgeusia, Incorrect route of drug administration, Wrong drug administered
Clinical narrative: This case was reported by a healthcare professional and described the occurrence of strange taste in an adult subject of unspecified gender who was vaccinated with Fluarix (GlaxoSmithKline). Previous and/or concurrent vaccination included DTaP; manufacturer unspecified given on 9 December 2007; hepatitis B vaccine recombinant ; manufacturer unspecified given on 9 December 2007; hepatitis A inactivated ; manufacturer unspecified given on 9 December 2007. On 9 December 2007 the subject received unspecified dose of Fluarix (.5 ml, unknown) intranasally (intramuscular formulation administered by other route) and experienced a funny taste. The same day, the subject was later vaccinated with Fluarix and experienced accidental overdose. No other adverse events were reported. In December 2007, the events were resolved. Outcome of accidental overdose was not specified. The healthcare professional considered the events were probably related to vaccination with Fluarix (causality not provided for accidental overdose). Follow-up information received on 14 January 2008 indicated that the intramuscular formulation of vaccine was mistaken as "Flumist" and administered intranasally. There were no other adverse events other than "bad taste."
Age: 65.0
Sex: F
Vaccine: FLU3
Symptoms: Urticaria
Clinical narrative: This case was reported by a physician and described the occurrence of hives in an approximately 66 year old female subject who was vaccinated with FLUARIX (GlaxoSmithKline). On 2 November 2007 the subject received unspecified dose of Fluarix (unknown). At an unspecified time after vaccination with Fluarix, the subject experienced hives. At the time of reporting the outcome of the event was unspecified.
Age: 13.0
Sex: F
Vaccine: FLU3
Symptoms: Immediate post-injection reaction, Injection site erythema, Injection site pain, Injection site warmth, Medication error
Clinical narrative: This case was reported by a pharmacist and described the occurrence of injection site redness in a 13-year-old female subject who was vaccinated with Fluarix (GlaxoSmithKline).  No concurrent medications.  On 7 December 2007 at 15:00 the subject received 1st dose of Fluarix (unknown, left arm).  Immediately after vaccination with Fluarix, the subject experienced injection site soreness and within hours experienced injection site redness and heat at injection site.  The subject also experienced vaccination error.  At the time of reporting the outcome of the redness at the injection site and heat at the injection site was resolved.  Soreness at the injection site was unresolved.
Age: 59.0
Sex: F
Vaccine: FLUX
Symptoms: Ear pain, Expired drug administered, Malaise, Pharyngolaryngeal pain
Clinical narrative: This case was reported by a consumer and described the occurrence of ear pain in a 59-year-old female subject who was vaccinated with Influenza vaccine (GlaxoSmithKline). A physician or other health care professional has not verified this report. Concurrent medical conditions included codeine allergy, penicillin allergy and sulfa allergy. On 8 October 2007 at 08:15 the subject received unspecified dose of Influenza vaccine (.5 ml, unknown, left arm) that has expired in the summer of 2007 (expired vaccine used). On 22 October 2007, 14 days after vaccination with Influenza vaccine, the subject experienced ear pain, throat pain, and was sick. The subject was treated with Levaquin for her sickness and it took a week for her to recover. At the time of reporting the events were resolved.
Sex: U
Vaccine: FLUX
Symptoms: Dizziness, Inner ear disorder, Nausea, Vomiting
Clinical narrative: This case was reported by a consumer and described the occurrence of dizziness in an unknown number of subjects of unspecified ages and gender who were vaccinated with Influenza vaccine (manufacturer unspecified). A physician or other health care professional has not verified this report. In 2007, the subjects received unspecified doses of Influenza vaccine (unknown). The reporter stated he "talked with numerous people who have experienced dizziness, inner ear problems, nausea and vomiting after receiving the flu shot this year". At the time of reporting the outcome of the events were unspecified.
Age: 40.0
Sex: M
Vaccine: FLUX
Symptoms: Dizziness, Inner ear disorder, Nausea, Vomiting
Clinical narrative: This case was reported by a consumer and described the occurrence of dizziness in an male subject aged between 40 and 49 years old who was vaccinated with Influenza vaccine, manufacturer unspecified). A physician or other health care professional has not verified this report. In 2007, the subject received an unspecified dose of Influenza vaccine (unknown). The reporter stated he "a farmer in his 40s experienced dizziness, inner ear problems, nausea and vomiting after receiving the flu shot this year". At the time of reporting the outcome of the events were unspecified. This case was assessed as medically serious by manufacturer. At the time of reporting the events were resolved.
Sex: U
Vaccine: FLUX
Symptoms: Dizziness, Inner ear disorder, Nausea, Vomiting
Clinical narrative: This case was reported by nurse, via consumer and described the occurrence of dizziness in an unknown number of subjects of unspecified ages and gender who were vaccinated with Influenza vaccine (manufacturer unspecified). A physician or other health care professional has not verified this report. In 2007, the subjects received unspecified doses of Influenza vaccine (unknown). The reporter stated he "talked with a nurse who stated she had patients who experienced dizziness, inner ear problems, nausea and vomiting after receiving the flu shot this year". At the time of reporting the outcome of the events were unspecified.
Sex: U
Vaccine: FLUX
Symptoms: Dizziness, Inner ear disorder, Nausea, Vomiting
Clinical narrative: This case was reported by a consumer, via his father and described the occurrence of dizziness in an unknown number of subjects of  unspecified ages and gender who were vaccinated with Influenza vaccine, manufacturer unspecified. A physician or other health care professional has not verified this report. In 2007, the subjects received unspecified doses of Influenza vaccine (unknown0. The reporter stated his son "has known individuals who have experienced dizziness, inner ear problems, nausea and vomiting after receiving the flu shot this year". At the time of reporting the outcome of the events were unspecified.
Sex: F
Vaccine: FLUX
Symptoms: Pain in extremity
Clinical narrative: This case was reported by a consumer, via manufacturer and described the occurrence of pain in arm post vaccination in a female subject of unspecified age who was vaccinated with Influenza vaccine, manufacturer unspecified). A physician or other health care professional has not verified this report. On an unspecified date the subject received unspecified dose of Influenza vaccine (unknown). At an unspecified time after vaccination with Influenza vaccine, the subject experienced pain in arm post vaccination. The subject reported "when she receives her yearly flu vaccine (manufacturer unknown) her arm hurts." No other information was provided.
Sex: F
Vaccine: FLUX
Symptoms: Influenza, Similar reaction on previous exposure to drug, Vaccination failure
Clinical narrative: This case was reported by a consumer and described the occurrence of influenza in a female subject of unspecified age who was vaccinated with influenza virus vaccine (Influenza vaccine (unspecified), manufacturer unspecified). A physician or other health care professional has not verified this report. On an unspecified date, the subject received an unspecified dose of Influenza vaccine (manufacturer unspecified). At an unspecified time after vaccination with an Influenza vaccine, the subject experienced influenza, vaccination failure and allergic to flu shots. Per the source document: "Patient can't get the flu shot (manufacturer unknown) because they are allergic. When they have received the flu shot they have gotten the flu. No further information was provided." This case was assessed as medically serious by GSK. At the time of reporting, the outcome of the events was unspecified.
Sex: M
Vaccine: FLU3
Symptoms: Injection site discolouration, Injection site swelling, Wrong technique in drug usage process
Clinical narrative: This case was reported by a pharmacist and described the occurrence of extensive swelling of vaccinated limb in a male subject aged between 50 and 59 years old who was vaccinated with FLUARIX (GlaxoSmithKline) . It was noted that the subject was very heavy. On 24 December 2007 the subject received unspecified dose of FLUARIX (.5 ml prefilled syringe) in his left leg. It was reported that an intramuscular needle was not used and the vaccine may have been administered subcutaneously. On 25 December 2007, 1 day after vaccination with FLUARIX, the subject experienced extensive swelling of vaccinated limb and skin discoloration at injection site. The reporter stated that the subject had a "severe site reaction that was 8 x 10 in size, purple and swollen." At the time of reporting the outcome of the events were unspecified.
Age: 24.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Asthenia, Blood test, Myelitis transverse
Clinical narrative: Numbness, tingling, heaviness in right arm from the shoulder down to the hand & fingers.
Age: 24.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Hypoaesthesia, Paraesthesia, Sensation of heaviness
Clinical narrative: Numbness, tingling, heaviness in right arm from the shoulder down to the hand & fingers.
Age: 24.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Electromyogram, Hypoaesthesia, Laboratory test, Oedema peripheral, Paraesthesia
Clinical narrative: Numbness, tingling, heaviness in right arm from the shoulder down to the hand & fingers.
Age: 24.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Sensation of heaviness
Clinical narrative: Numbness, tingling, heaviness in right arm from the shoulder down to the hand & fingers.
Age: 15.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Colonoscopy, Computerised tomogram, Computerised tomogram abnormal, Diarrhoea haemorrhagic, Facial palsy
Clinical narrative: 24 hours after dose diarrhea developed became bloody after one month.  All stool tests neg, CT; GI consult - UGI, SB, LGI, and colonoscopy. *Bells Palsy 1/22/08. Cont with diarrhea x10 per day.
Age: 15.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Stool analysis abnormal, Thyroid function test abnormal, X-ray with contrast lower gastrointestinal tract, X-ray with contrast upper gastrointestinal tract
Clinical narrative: 24 hours after dose diarrhea developed became bloody after one month.  All stool tests neg, CT; GI consult - UGI, SB, LGI, and colonoscopy. *Bells Palsy 1/22/08. Cont with diarrhea x10 per day.
Age: 15.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Colonoscopy, Computerised tomogram, Diarrhoea haemorrhagic, Facial palsy, Stool analysis normal
Clinical narrative: 24 hours after dose diarrhea developed became bloody after one month.  All stool tests neg, CT; GI consult - UGI, SB, LGI, and colonoscopy. *Bells Palsy 1/22/08. Cont with diarrhea x10 per day.
Age: 15.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: X-ray with contrast upper gastrointestinal tract
Clinical narrative: 24 hours after dose diarrhea developed became bloody after one month.  All stool tests neg, CT; GI consult - UGI, SB, LGI, and colonoscopy. *Bells Palsy 1/22/08. Cont with diarrhea x10 per day.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Back pain, Hallucination, Headache, Hyperaesthesia, Nausea
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Pyrexia, Vomiting
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Abdominal tenderness, Abnormal dreams, Back pain, Blood test normal, Body temperature increased
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Dyspnoea, Haematochezia, Hallucination, Headache, Lumbar puncture
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Nausea, Neurological examination abnormal, Occult blood positive, Physical examination abnormal, Pyrexia
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Scan, Vasculitis, Visual disturbance
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Activities of daily living impaired, Asthenia, Back pain, C-reactive protein increased, Computerised tomogram normal
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Gait disturbance, Headache, Lumbar puncture, Nausea, Neurological examination abnormal
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Nuclear magnetic resonance imaging normal, Physical examination normal, Pyrexia, Red blood cell sedimentation rate normal, Vaccination complication
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.
Age: 17.0
Sex: F
Vaccine: HPV4, HPV4, HPV4
Symptoms: Vasculitis
Clinical narrative: Information has been received from a physician concerning a 17 year old female, who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient experienced severe back pain, weakness (more subjective then objective), low grade fever for a day or two, nausea, and a bad headache. The patient missed more than a week of school. It was reported that all laboratories performed were negative including a sedimentation rate of 4mm/hr. However, the patient's CRP was about 40mg/liter (same as 4mg/dL in lab). The patient's CRP normalized within one week. A neurological exam showed slow gait. The patient's DTR and motor strength were normal. The patient had an extensive radiological evaluation including a normal computed axial tomography (CT) scan of the head followed by a normal lumbar puncture (LP), normal magnetic resonance imaging (MRI) of the spine and sacroiliac joint with and without contrast, and a normal CT scan of the abdomen with and without contrast. The patient's mother took her to be seen by an internal medicine physician. The physician diagnosed the patient with vasculitis. The physician treated the patient with prednisone 60mg/day. It was reported that the patient significantly improved on the corticosteroid, which reinforced the diagnosed of vasculitis. The patient had been admitted to the hospital for several days in order to be evaluated. At the time of the report, the outcome of the patient was unknown. The physician made a definite connection to the patient's symptoms and the vaccination. Additional information has been requested.